The observation that both Enarodustat[96] and Desidustat[97] manifest relatively efficient inhibition of isolated JMJD6 is of interest given that they are approved for clinical use.[98,117] The short‐ and long‐term effects of JMJD6 inhibition by Enarodustat[96] and Desidustat[97] should therefore be investigated, given that they are used over a relatively long time period to treat CKD‐associated anemia. This evidence concerns the gene JMJD6 and chronic kidney disease.